About me

Dr. José M. Miró is Senior Consultant of Infectious Diseases at the Hospital Clinic of Barcelona, Professor of Medicine at the University of Barcelona, and Director of the Master on AIDS of the University of Barcelona. Dr. Miro is an accredited IDIBAPS researcher who has two research lines: 1) Infective endocarditis (including the experimental model), as Group leader (R4); and, HIV/AIDS (epidemiological studies in HIV cohorts, primary HIV-1 infection, tuberculosis and other opportunistic Infections, clinical trials in advanced patients and solid organ transplantation in HIV-1 infected patients), as R3A researcher. Dr. Miro has published 800 articles in peer-review journals (h-index 72).

Featured publications

  • Outpatient Parenteral Antibiotic Treatment (OPAT) for Infective Endocarditis: a Prospective Cohort Study From the GAMES Cohort

    Authors: Pericà S JM, Llopis J, González-Ramallo V, Goenaga MÁ, Muñoz P, García-Leoni ME, Fariñas MC, Pajarón M, Ambrosioni J, Luque R, Goikoetxea J, Oteo JA, Carrizo E, Bodro M, Reguera-Iglesias JM, Navas E, Hidalgo-Tenorio C, Miró JM, Spanish Collaboration on Endocarditis-Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) investigators.
    Reference: Clinical Infectious Diseases 2019; 69(10):1690-1700.
  • Infective endocarditis: an ongoing global challenge

    Authors: Miro JM, Ambrosioni J .
    Reference: EUROPEAN HEART JOURNAL 2019.
  • HIV Infection Does Not Worsen Prognosis of Liver Transplantation for Hepatocellular Carcinoma

    Authors: Agüero F, Forner A, Manzardo C, Valdivieso A, Blanes M, Barcena R, Rafecas A, Castells L, Abradelo M, Torre-Cisneros J, Gonzalez-Dieguez L, Salcedo M, Serrano T, Jimenez-Perez M, Herrero JI, Gastaca M, Aguilera V, Fabregat J, Del Campo S, Bilbao I, Romero CJ, Moreno A, Rimola A, Miro JM, FIPSE Investigators.
    Reference: HEPATOLOGY 2016; 63(2):488-498.
  • Short-course antiretroviral therapy in primary HIV infection

    Authors: , Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, Rees H, Fisher M, Schechter M, Kaleebu P, Tambussi G, Kinloch S, Miro JM, Kelleher A, McClure M, Kaye S, Gabriel M, Phillips R, Weber J, Babiker A SPARTAC Trial Investigators.
  • Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial. (vol 43, pg 79,

    Authors: Miro, J. M.; Lopez, J. C.; Podzamczer, D.; Pena, J. M.; Alberdi, J.; Martinez, E.; Domingo, P.; Cosin, J.; Claramonte, X.; Arribas, J. R.; Santin, M.; Ribera, E.;.
  • Staphylococcus aureus native valve infective endocarditis: Report of 566 episodes from the International Collaboration on Endocarditis Merged Database

    Authors: Miro, JM; Anguera, I; Cabell, CH; Chen, AY; Stafford, JA; Corey, GR; Olaison, L; Eykyn, S; Hoen, B; Abrutyn, E; Raoult, D; Bayer, A; Fowler, VG;Int Collaboration Endocarditis.
    Reference: CLINICAL INFECTIOUS DISEASES 2005; 41(4):507-514.
  • Staphylococcus aureus endocarditis - A consequence of medical progress

    Authors: Fowler, VG; Miro, JM; Hoen, B; Cabell, CH; Abrutyn, E; Rubinstein, E; Corey, GR; Spelman, D; Bradley, SF; Barsic, B; Pappas, PA; Anstrom, KJ; Wray, D; Fortes, CQ; Anguera, I; Athan, E; Jones, P; Van Der Meer, Jtm; Elliott, Tsj; Levine, DP; Bayer, AS.
    Reference: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 2005; 293(24):3012-3021.

Featured Projects

  • Intensified tuberculosis treatment to reduce the high mortality of tuberculous meningitis in HIV-infected and uninfected patients

    Principal investigator: José María Miró Meda
    Duration: 01/01/2019 - 31/12/2023
  • Eficacia de nuevas pautas de tratamiento antibiótico de la endocarditis enterocócica evaluadas in vitro y en el modelo de endocarditis experimental.

    Principal investigator: J.M. Miró
    Code: PI17/01251
    Duration: 01/01/2018 - 01/01/2020
  • Reconstitución inmune en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3 que reciben un régimen de fármacos antirretrovirales basado en dolutegravir o darunavir/ritonavir. Estudio Adva

    Principal investigator: José María Miró Meda, Josep M. Miró Meda
    Code: 2014-002281-70
    Duration: 01/01/2015
  • A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients with Intravenous Catheter associated Blood Stream Infections due to Staphylococci

    Principal investigator: Josep M. Miró Meda
    Duration: 01/01/2011 - 31/12/2017